Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial. The trial evaluated fixed treatment duration epcoritamab in combination with rituximab and standard of care, demonstrating a statistically significant improvement in progression-free survival for patients with newly diagnosed di
Genmab A/S – ADR (NASDAQ: GMAB ) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory